Statin therapy in critical illness: an international survey of intensive care physicians’ opinions, attitudes and practice

Table 1 Cut offs for biochemical tests below which the respondents would enrol patients into the proposed trial

THRESHOLD	OVERALL (%)			UK (%)			ANZ (%)
THRESHOLD	ALT/AST	CK	BILIRUBIN	ALT/AST	CK	BILIRUBIN	ALT/AST	CK	BILIRUBIN
uln	27.6	34.7	33.9	31.6	41.8	38.4	16.1	14.5	21.0
3 uln	42.3	33.9	37.7	36.7	26.0	32.2	58.1	56.5	53.2
5 uln	13.8	13.4	12.1	11.3	10.7	8.5	21.0	21.0	22.6
10 uln	2.5	2.9	1.7	2.3	2.8	1.7	3.2	3.2	1.6
>10 uln	0.4	1.7	1.3	0	0.6	1.1	1.6	4.8	1.6
missing/no response	13.4	13.4	13.4	18.1	18.1	18.1	0	0	0
total	100	100	100	100	100	100	100	100	100

Shows the biochemical cut offs for hepatic transaminases (ALT/AST), creatine kinase (CK) and total bilirubin (bilirubin) below which the respondents would consider enrolling patients in the proposed statin interventional trial. Data are presented as proportions. ULN = upper limit of normal. p = 0.007 for ALT/AST; p < 0.001 for CK; p = 0.003 for Bilirubin (p-values when comparing the overall frequency distribution of the responses for ANZ and UK).